The long-term impact of neovascular age-related macular degeneration undergoing routine treatment in first and second eyes on vision-related quality-of-life: FASBAT Report 3

Macular Diseases

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Grimaldi G, Bartolomeo N, Garweg JG, Pfister IB, Schild C, Peyla A, Tillmann A, De Oliveira Figueiredo EC, Spitznagel T, Kitay AM, Gabathuler F, Zweifel S, Kurz-Levin MM, Ebneter A, Somfai GM, Eandi CM, Munk MR, Ambresin A, Menghini M

doi: 10.1007/s40123-025-01305-w

Macular DiseasesRetinal Diseases

One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Tillmann A, Stillenmunkes R, Garweg JG, Cattaneo J, Bartolomeo N, Grimaldi G, Spitznagel T, De Oliveira Figueiredo EC, Ambresin A, Menghini M, Somfai GM, Zweifel S, Fröhlich J, Artemiev D, Ebneter A, Hatz K, Weinberger A, Pfister IB, Schild C, Eandi C, Munk MR, Swiss Retina Research Network

doi: 10.1007/s40123-025-01252-6

Macular Diseases

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Kitay AM, Tillmann A, Pfister I, Schild C, Bonanata M, Heck K, Spitznagel T, Gabathuler F, Bartolomeo N, Magnin S, Löliger J, Munk MR, Menghini M, Hatz K, Somfai GM, Zweifel S, Ambresin A, Eandi CM, Feltgen N, Weinberger A, Garweg JG, Kurz-Levin MM

doi: 10.1007/s40123-026-01344-x

Macular DiseasesRetinal Diseases

Incidence and associations of Retinal pigment epithelial (RPE) tear post-loading phase of aflibercept 2mg in Treatment Naïve Neovascular Age-Related Macular Degeneration (nAMD): PRECISE study report 10

Retina

Kazantzis D, Thottarath S, Sheemar A, Keskin AM, Kubravi HS, Sivaprasad S, PRECISE Study Group

doi: 10.1097/IAE.0000000000004985

Macular Diseases

Age-Specific Increases in the Prevalence and Treatment Burden of Neovascular Age-Related Macular Degeneration in a Super-Aged Society

Invest Ophthalmol Vis Sci

Akada M, Ideyama M, Kido A, Miyata M, Ueda-Arakawa N, Tamura H, Ooto S, Miyake M, Tsujikawa A, Hata M

doi: 10.1167/iovs.67.4.19

Macular Diseases

Nonexudative Macular Neovascularization in Age-Related Macular Degeneration

JAMA Ophthalmol

Thottarath S, Gurudas S, Kubravi S, Kazantzis D, Keskin AM, Sivaprasad S, EYENEON Study Group

doi: 10.1001/jamaophthalmol.2026.0459

Macular Diseases

Evaluating the risk of recurrence in neovascular age-related macular degeneration using OCT-angiography at the time of treatment exit

Br J Ophthalmol

Jaggi D, Marugg S, Berger LE, Munk MR, Zinkernagel MS, Heussen FM

doi: 10.1136/bjo-2025-327721

Macular Diseases

Discontinuing Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration That Remains Inactive with Treatment at the Maximum Injection Interval

Clin Ophthalmol

Şatırtav G, Lövestam-Adrian MK, Chang W, Charles M, Chen LJ, Cheung CMG, Kodjikian L, Ohji M, Zinkernagel M, Wolf S

doi: 10.2147/OPTH.S587803

Macular Diseases

Ten-Year Incidence, Risk Factors and Progression Rate of Macular Atrophy in Neovascular Age-Related Macular Degeneration

Clin Exp Ophthalmol

Romano F, Casaluci M, Valastro A, Airaldi M, Milella P, Pozzo Giuffrida F, Cozzi E, Aretti A, Teo KY, Cheung CMG, Nassisi M, Viola F, Staurenghi G, Invernizzi A

doi: 10.1111/ceo.14608

Related content

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Incidence and associations of Retinal pigment epithelial (RPE) tear post-loading phase of aflibercept 2mg in Treatment Naïve Neovascular Age-Related Macular Degeneration (nAMD): PRECISE study report 10

Age-Specific Increases in the Prevalence and Treatment Burden of Neovascular Age-Related Macular Degeneration in a Super-Aged Society

Nonexudative Macular Neovascularization in Age-Related Macular Degeneration

Evaluating the risk of recurrence in neovascular age-related macular degeneration using OCT-angiography at the time of treatment exit

Discontinuing Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration That Remains Inactive with Treatment at the Maximum Injection Interval

Ten-Year Incidence, Risk Factors and Progression Rate of Macular Atrophy in Neovascular Age-Related Macular Degeneration